Apixaban Leads Bleeding Safety Over Rivaroxaban in Acute VTE, Study Finds
TL;DR
COBRRA (2760 patients, 3 months) shows apixaban reduces clinically relevant bleeding vs rivaroxaban in acute VTE (3.3% vs 7.1%), with major and clinically relevant nonmajor bleeding also lower (0.4% vs 2.4%; 2.9% vs 4.9%), while recurrent symptomatic VTE is similar (~1%). The safety edge could shift guidelines and insurer preference toward apixaban, though the study’s short follow-up and predominantly White population are limitations; a COBRA-AF trial in atrial fibrillation is planned.
- VTE Trial: As DOACs Face Off, Apixaban Confirmed Safer Medscape
- Blood-thinning drug Eliquis likely safer for patients with deep blood clots, study suggests CBC
- Safer treatment for venous thrombosis McGill University Health Centre
- Safeguarding Blood Clot Patients: Eliquis Takes Lead Over Xarelto Devdiscourse
- Safer blood clot treatment: Apixaban beats rivaroxaban in head-to-head comparison Medical Xpress
Want the full story? Read the original reporting
Read on Medscape